It is known that GH stimulates bone turnover and that GH-deficient adults have a lower bone mass than healthy controls. In order to evaluate the influences of GH replacement therapy on markers of bone turnover and on bone mineral density (BMD) Compared with placebo, after 6 months serum calcium (2\m=.\39\m=+-\0\m=.\02 vs 2\m=.\32\m=+-\0\m=.\02mmol/l, P=0\m=.\037) and phosphate (0\m=.\97\m=+-\0\m=.\06 vs 0\m=.\75\m=+-\0\m=.\05 mmol/l, P=0\m=.\011) increased and the index of phosphate excretion (0\m=.\03\m=+-\0\m=.\03vs 0\m=.\19\m=+-\0\m=.\02,P<0\m=.\001) decreased significantly, and there was a significant increase in the markers of bone formation (osteocalcin, 64\m=.\8\m=+-\11\m=.\8vs 17\m=.\4\m=+-\1\m=.\8 ng/ml, P<0\m=.\001; procollagen type I carboxyterminal propeptide (PICP), 195\m=.\3\m=+-\26\m=.\4vs 124\m=.\0\m=+-\15\m=.\5 ng/ml, P=0\m=.\026) as well as those of bone resorption (type I collagen carboxyterminal telopeptide (ICTP), 8\m=.\9\m=+-\1\m=.\2vs 3\ m=. \ 3\ m=+-\ 0\ m=. \ 5 ng/ml, P<0\m=.\001; urinary hydroxyproline, 0\m=.\035\m=+-\0\m=.\006vs 0\m=.\018\m=+-\0\m=.\002 mg/ 100 ml glomerular filtration rate, P=0\m=.\009). BMD did not change during this period of time. IGF-I was significantly higher in treated patients (306\m=.\5\m=+-\45\m=.\3vs 88\m=.\7\m=+-\22\m=.\5 ng/ml, P<0\m=.\001).
Introduction
Growth hormone (GH) plays an important role in the regulation of bone growth in childhood (modelling) and of bone remodelling in adulthood. Most of its effects on bone are mediated either by circulating or by locally produced insulin-like growth factor-I (IGF-I). Adult patients with both childhood GH deficiency or with adult onset have been shown to have a reduced bone mass compared with normal controls (1) (2) (3) (4) . Patients with acromegaly often have an increased bone density in the peripheral skeleton while it may be diminished in the axial skeleton (5) , probably through the concomi¬ tant lack of sex hormones. Studies of GH replacement therapy in GH-deficient adults with either childhood or adult onset have shown an increase in bone turnover with stimulation of bone formation as well as bone résorption measured by biochemical markers of bone metabolism (6) (7) (8) (9) (10) (11) (12) (13) . The effects on bone mass, measured by different methods, have, however, been inconsistent, some studies showing an increase (9, 14, 15) and others showing no change or even a decrease (8, 10-13, [16] [17] [18] [19] . The population in these studies was not homogeneous with regard to the age of onset of GH deficiency.
The aim of the present study was to evaluate the short-term and long-term effects of GH replacement therapy on bone metabolism and mineral density (measured by dual energy x-ray absorptiometry (DXA)) in a well-defined group of patients with adult onset GH deficiency.
Patients and methods
Patients and study protocol Twenty patients aged between 22 and 59 years with adult onset GH deficiency were studied ( Table 1) . None Urinary calcium/creatinine (mmol/mg) Compared with placebo, treatment with rhGH resulted in significant increases in serum calcium at month 6 and serum phosphate at months 3 and 6, whereas calcium excretion did not differ. Phosphate excretion decreased substantially ( Table 2) .
Markers of bone formation increased in the rhGHtreated patients. The differences in relation to the placebo group were highly significant at months 3 and 6 for osteocalcin and PICP, whereas weakly significant increases for total AP and bone AP were found only at The most striking result of our study was the highly significant increase of the markers of bone turnover, combined with an increase in BMD at the lumbar spine and the proximal femur after long-term treatment. As an anabolic hormone, GH is important in the regulation of bone metabolism, growth and remodelling, most of its effects being mediated by ÍGF-I, generated either systemically or locally. IGF-I levels were subnormal in our patients before the start of rhGH therapy and rose to levels in the normal range for young adults, which is highly significant compared with placebo or with baseline. These normal levels were maintained throughout the study.
Of the bone formation markers, osteocalcin, and of the résorption markers, ICTP, showed the highest increases compared with placebo in the placebocontrolled study as well as compared with baseline in the extended open study. The other markers of bone turnover (Tables 2 and 4 ) behaved similarly but the increases were less extensive. Similar results have been described in most of the former studies; few of them, however, had treatment periods for more than 6 months (9, (11) (12) (13) sites except total body, although a positive trend can also be recognised in this area (Table 5 and Fig. 1 (23) .
The quantitative effects of GH replacement therapy on BMD in our study and that of Vandeweghe et al. (9) in GH-deficient adults compare favourably with those achieved by drugs used in the treatment of post¬ menopausal osteoporosis, such as calcitonin (24) , bisphosphonates (25) 
